The safety of GLP-1RAs regarding the development of DR is supported by the LEADER trial, which demonstrated no statistically significant difference in rates of DR in those receiving liraglutide compared to placebo
For systemic benefit, injection wins
Sesame's own site states clinical trial results for two of the medications it offers, according to the brand's description of manufacturer research and labeling: Wegovy: average weight loss of 14% after 64 weeks, reaching 17% with continued treatment, combined with a reduced-calorie diet and increased activity Zepbound and other tirzepatide-based options: a range of 15% to 20% body weight reduction with proper nutrition and exercise This article has not independently pulled the FDA-approved prescribing information for each drug, and none of it reflects an independent study of Sesame's platform or its outcomes
However, research on the effectiveness of Lipo B12 Shots is limited, and they should not be viewed as a magic solution for weight loss
Subtle conformational dynamics allow the C-terminus of GLP-1 to access the ECD binding site, and the ligand binding triggers further dissociation of the ECD from the TMD allowing the N-terminus of GLP-1 to enter the orthosteric pocket in the TMD and activate the receptor